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Abstract
Background: The Rotapro study was conducted to evaluate the safety and feasibility of the 
new Rotapro rotational atherectomy system (RAS) for lesion preparation in calcified 
coronary artery stenosis.
Methods: Between 2015 and 2019 consecutive patients undergoing rotational atherectomy 
(RA) with the new Rotapro system and the conventional rotablator (Rotablator) were 
included from the Bad Krozingen Rotablation Registry. The primary endpoint was the 
incidence of in-hospital major adverse cardiovascular and cerebral event rate (MACCE). 
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Results: Rotablation was performed in 3.6% of all patients (n = 597) treated by percutaneous
coronary intervention. Procedural outcomes were compared according to the applied RAS (n 
= 246 Rotapro vs. n = 351 Rotablator). Overall technical success was achieved in 98.3% of 
patients. The primary endpoint of in-hospital MACCE was comparable between the Rotapro- 
and the Rotablator-group (3.7% vs. 5.7%, respectively, p = 0.254). The Rotapro group was 
associated with significant reductions of fluoroscopy time (30 vs. 38 min, p < 0.0001), 
procedural time (82.5 vs. 96 min, p = 0.0003), applied contrast volume (210 vs. 290 mL, p < 
0.0001) and radiation dose (6129 vs. 9827 cGy*cm2, p < 0.0001) compared to the Rotablator 
group. 
Conclusions: The present study demonstrates the safety and efficacy of the new Rotapro 
system. In-hospital MACCE rates were comparable between both RAS, whereas Rotapro was
associated with less fluoroscopy time, radiation dose as well as contrast use. 
Key words: percutaneous coronary intervention, rotational atherectomy, coronary 
artery disease
Introduction 
Advances in treating calcified lesions with percutaneous coronary intervention (PCI) 
have improved patient outcomes and prognosis during recent years. PCI of calcified coronary
lesions remains challenging regarding optimal stent delivery and expansion [2]. Adequate 
lesion preparation is fundamental for sufficient stent expansion prior to stent implantation. 
Nevertheless, PCI of calcified lesions is associated with higher rates of re-stenosis and target 
lesion failure [3]. Rotational atherectomy (RA) is considered as an important device for stent 
delivery and complete stent expansion in calcified lesions [4, 5]. Recently, Abdel-Wahab et 
al. [6] showed the feasibility of using RA in patients with severely calcified lesions without 
excessive late lumen loss in the randomized PREPARE-CALC trial. The present study 
analyzed patients with calcified lesions undergoing PCI using RA with either the new 
Rotapro rotational atherectomy system (RAS) or the conventional Rotablator (Boston 




Patients undergoing PCI with RA were included in the Bad Krozingen rotablation 
registry from January 2015 to December 2019. In September 2018, the new RAS from 
Boston scientific (Rotapro) was installed at the documented institution. Data collection 
included all patients treated by RA in severely calcified lesions with either the new Rotapro 
RAS or the conventional Rotablator. Written informed consent for PCI was obtained from 
each patient and the collection of data was performed in accordance with the Declaration of 
Helsinki and was approved by the institutional review board (Ethical approval number: EK 
21-1100). All angiographic results were analyzed by two independent interventional 
cardiologists reviewing coronary angiograms and procedure-related data were obtained 
retrospectively from source data and related documentation.
RA procedure and postinterventional management
The decision to perform RA was at the operators’ discretion and RA was performed 
upfront due to heavy calcification of the target lesion or after failed PCI attempts due to non-
dilatable or uncrossable calcified lesion. Severe calcification of the target lesion was defined 
by cine angiography (i.e. radiopacities noted without cardiac motion before contrast injection 
generally compromising both sides of the arterial lumen) [8]. All RA PCI were performed by 
high-volume PCI operators using Rotablator and since September 2018 the Rotapro RAS 
(Boston Scientific Corp., Natick, MA) (i.e. defined by a minimum of n = 50 RAs performed 
each year). Vascular access, burr size and ablation speed were left to the operators’ discretion.
Heparin and nitroglycerin were given during RA as continuous infusion. Atropin was given 
prior to RA and pacemaker was present just in case of persistent bradycardia after atropin as 
recommended [9]. The initial burr size was chosen by the operators due to the reference 
vessel diameter (burr: artery ratio ≤ 0.7) [10]. RA speed was chosen by the operators and RA 
was started over a RotawireTM (Boston Scientific) with an initial rotational speed of 160.000 
rpm to 180.000 rpm. Postinterventional 12 leads electrocardiogram were documented 24 
hours after PCI and cardiac markers (CK, CK-MB and troponin) were measured after 8, 16 
and 24 hours. In addition, patients were clinically monitored during the whole hospital stay. 
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Study endpoints
The primary endpoint was the incidence of in-hospital major adverse cardiovascular 
and cerebral event rate (MACCE) defined as the composite of in-hospital all-cause death, 
periprocedural myocardial infarction, recurrent symptoms requiring urgent target vessel 
revascularization with PCI or surgery, and stroke. Periprocedural myocardial infarction was 
defined using by the fourth universal definition (type 4a) [11].  
Secondary endpoints were procedural success, defined as technical success without 
in-hospital MACCE, procedural time, fluoroscopy time, the amount of contrast used, as well 
as major complications defined as vascular access complications and pericardiocentesis. 
Technical success was defined as successful revascularization of occlusive and non-occlusive
coronary lesions with achievement of < 30% residual diameter stenosis within the treated 
segment and restoration or maintenance of Thrombolysis in Myocardial Infarction (TIMI) 
grade 3 antegrade flow.
Statistical analysis
The continuous data are presented as mean ± standard deviation or median 
(interquartile range [IQR]) unless otherwise specified and were compared using the Student t-
test. Wilcoxon rank-sum test and the Kruskal-Wallis test were applied for non-parametric 
continuous variables, as appropriate. Categorical variables were expressed as percentages and
were compared using the Pearson chi-square test or Fisher exact test. Multivariable logistic 
regression model with backward elimination were developed using the primary endpoint of 
in-hospital MACCE as the dependent variable. Furthermore, multivariable logistic regression 
models with backward elimination were developed using fluoroscopy time above the median 
of each evaluated subgroup as the dependent variable. The multivariable models were 
adjusted for confounding independent variables, which were significantly different between 
the Rotapro and the Rotablator group regarding baseline, angiographic and PCI-related 
characteristics. Corresponding odds ratios with 95% confidence intervals (95% CI) were 
presented. All statistical analyses were performed with JMP 13.0 (SAS, Cary, North Carolina,
USA). A two-sided p value of 0.05 was considered statistically significant.
Results
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Baseline and angiographic characteristics 
Out of 16,317 PCIs from 2015 to 2019, a total of 597 (3.6%) consecutive PCI with 
RA were included. The Rotapro RAS was used in 246 (41.2%), whereas the Rotablator was 
used in 351 (58.8%) PCI. Baseline and angiographic characteristics are outlined in Tables 1–
3. Acute coronary syndromes, prior coronary artery bypass grafting, excentric calcified lesion
and intra-lesion angulation were significantly more frequent in the Rotablator group than in 
the Rotapro group. Annual frequencies of RA increased yearly from 2015 to 2019 (1.6–6.9%, 
Suppl. Table 1). 
Characteristics related to PCI and RAS
As shown in Table 3, PCI was performed with at least 6 F guides and upgraded up to 
8 F, based on the burr size used (1.25–2.0 mm). In the Rotapro group, radial access (40.70% 
vs. 28.70%), 7 Fr guides (65.50% vs. 52.90%), and greater balloon sizes (3.1 ± 0.5 mm vs. 
2.8 ± 0.6 mm) were more common. Both, number and total implanted stent lengths were 
similar in both groups (1.9 vs. 1.8 stents; 50.5 vs. 54.2 mm lengths). Significantly greater 
burrs were used in the Rotapro group.
Primary endpoint
The primary endpoint, in-hospital MACCE was comparable between both groups 
(3.7% vs. 5.7%, Rotapro vs. Rotablator, p = 0.254). Accordingly, the components of 
MACCE, such as rates of in-hospital mortality (2.4% vs. 2.6%, p = 0.923), periprocedural 
myocardial infarction (0.4% vs. 0.9%, p = 0.647), target vessel revascularization (2.9% vs. 
3.7%, p = 0.566) and stroke (0.0% vs. 0.3%, p = 1.0) were comparable in both groups. Within
univariable analysis patients with acute coronary syndrome on admission had significantly 
higher in-hospital MACCE (odds ratio [OR] 3.29, 95% CI 1.46–7.11, p = 0.0005), 
nevertheless acute coronary syndrome was not an independent predictor for in-hospital 
MACCE after multivariable adjustment (OR 1.86, 95% CI 0.65–4.65, p = 0.23) (Table 5). 
Secondary endpoints
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Technical success was comparable in both groups (99.2% vs. 98.3%, p = 0.385). As 
shown in Table 4, procedural time (82.5 vs. 96 min, p = 0.0003), fluoroscopy time (30 vs. 38 
min, p = 0.0001), contrast volume (210 vs. 290 mL, p = 0.0001) and radiation dosage (6129.5
vs. 9827 cGy*cm2, p = 0.0001) were significantly lower in the Rotapro group. Clinically 
relevant perforation with subsequent cardiac tamponade and pericardiocentesis occurred in 8 
(1.3%) patients. Coronary perforation requiring pericardiocentesis was numerically lower in 
the Rotapro group (0.8% vs. 1.7%, p = 0.348) (Table 4). Notably, parameters associated 
univariably with increased fluoroscopy time in each group are presented in Supplemental 
Tables 2 and 3. Within multivariable adjusted logistic regression models (Suppl. Tables 4A, 
B). CTO-PCI (Rotapro: OR 10.5, 95% CI 4.88–23.9, p = 0.0001, Rotablator: OR 5.22, 95% 
CI 95% 2.52–11.11, p = 0.0001) and the use of any femoral or dual access (Rotapro: OR 
2.73, 95% CI 1.24–6.14, p = 0.0118, Rotablator: OR 2.68, 95% CI 1.21–6.22, p = 0.0151) 
remained significantly associated with prolonged fluoroscopy time in both RAS groups.
Discussion
The present study was based on a large, consecutive cohort of patients undergoing RA
comparing the feasibility, safety and in-hospital outcome of the new Rotapro and the former 
Rotablator system. The major findings of this study are: (a) The use of the new Rotapro RAS 
is safe and comparable with regard to in-hospital MACCE and procedural success to the 
former Rotablator RAS; (b) The new Rotapro RAS was associated with lower procedural and
fluoroscopy time. 
Increasing amounts of coronary calcification is a relevant pathology during cardiac 
catherization worldwide. Aging of coronary artery disease patients and rapidly developing 
techniques for the treatment of complex coronary lesions by PCI have increased the 
proportion of applied RA PCI to overcome severely calcified coronary lesions over the last 
decade. The incidence of PCI performed in moderate to severe calcified coronary lesions was 
recently estimated at 19.6% [12]. This incidence was estimated even higher in patients with 
coronary three vessel disease. Within the SYNTAX (Synergy Between Percutaneous 
Coronary Intervention with Taxus and Cardiac Surgery) trial, severely calcified coronary 
lesions were reported in 32.7% of patients with coronary artery bypass grafting and 24.9% of 
patients treated with PCI [13]. Furthermore, patients with calcified lesions are accompanied 
6
with relevant comorbidities including diabetes mellitus, dyslipidemia, arterial hypertension 
and chronic kidney disease [14]. 
The interventional treatment of severely calcified CAD is challenging and associated 
with higher rates of peri-procedural failures and complications compared to PCI of non- or 
less calcified lesions [5]. Increased operators’ expertise, even in the application of devices to 
increase gear-related back-up support (e.g. by extra support wires, guiding extension, high-
pressure or modified balloons) are required to achieve optimal stent expansion. The technical 
principle of the RA device is to ablate the calcified atherosclerotic coronary plaque by 
advancing a high-speed diamond-incrusted elliptical burr in the coronary artery. RA has 
developed to the method of choice for lesion preparation to overcome severely calcified 
coronary artery disease within the past 30 years [18].
The new Rotapro RAS represents a more user-friendly handling for the operator due 
to an improved digital display, enhanced feedback, deceleration indicator, and on-side 
controller replacing the former foot pedal. Khalid et al. [15] recently reported data from the 
Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE)
database during a period of more than 3 years. Adverse events and device-related issues were 
documented both for the Rotapro (n = 63) and Rotablator (n = 363) RAS. It was 
demonstrated that RA devices are associated with higher incidences of coronary dissections, 
perforation and burr entrapment. Device-related issues including detachment and structural 
damages were reported in 39% in the Rotablator group, whereas device entrapment occurred 
in 47% in the Rotapro group. However, data on the procedural and clinical outcomes of 
patients treated with the new Rotapro RAS is lacking. 
According to available research, the present study is the first dedicated analysis of RA
using Rotapro. In the present trial, the in-hospital MACCE were comparable between both 
RAS. Technical and procedural success rates using RA were very high (98.7% and 93.8%, 
respectively) and did not show any meaningful trend. Notably, the new Rotapro system was 
associated with lower procedural time and less radiation exposure. Therefore, the present 
study demonstrated the safety and feasibility of the new Rotapro RAS.
Limitations of the study
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This study was based on a retrospective non-randomized single-center registry. 
Furthermore, the indication for RA-PCI and the selected device was left to the operators’ 
discretion and their technical expertise and selection bias may therefore not be excluded. Use 
of the former Rotablator RAS was associated with smaller 1.25 mm burrs, whereas severe 
complications were still comparable in RAS groups. A large prospective randomized 
controlled multi-center study is needed to investigate the optimal treatment strategy for 
plaque modification of uncrossable severely calcified lesions including the new Rotapro 
RAS. 
Impact on daily practice
The new Rotapro RAS is user-friendly and was associated with lower procedural 
time, despite comparable in-hospital MACCE and procedural success rates.
Conclusions
The present study demonstrates the safety and efficacy of using the new Rotapro 
RAS, which was associated with comparable in-hospital MACCE, lower procedural time, 
radiation exposure and contrast use compared to the former generation of RAS.
Conflict of interest: Mohamed Ayoub, MD: reports consulting/speaker/proctoring honoraria 
honoraria from Boston Scientific, Ashai Intecc, Medtronic, Terumo; Miroslaw Ferenc, MD: 
reports consulting honoraria from Boston Scientific; Kambis Mashayekhi reports 
consulting/speaker/proctoring honoraria from Abbott Vascular, Ashai Intecc, AstraZeneca, 
Biotronik, Boston Scientific, Cardinal Health, Daiichi Sankyo, Medtronic, Teleflex, Terumo; 
F.-J. Neumann reports lectures fees paid to his institution from Amgen, Bayer Healthcare, 
Biotronic, Boehringer Ingelheim, Boston Scientific, Daiichi Sankyo, Edwards Lifesciences, 
Ferrer, Pfizer, Novartis, consultancy fees paid to his institution from Boehringer Ingelheim 
and grant support from Bayer Healthcare, Boston Scientific, Biotronic, Edwars Lifesciences, 
GlaxoSmithKline, Medtronic, Pfizer, Abbot Vascular.
References
8
1. Li Q, He Y, Chen Li, et al. Intensive plaque modification with rotational atherectomy 
and cutting balloon before drug-eluting stent implantation for patients with severely 
calcified coronary lesions: a pilot clinical study. BMC Cardiovasc Disord. 2016; 16: 
112, doi: 10.1186/s12872-016-0273-8, indexed in Pubmed: 27230875.
2. Reifart N, Vandormael M, Krajcar M, et al. Randomized comparison of angioplasty of
complex coronary lesions at a single center. Excimer Laser, Rotational Atherectomy, 
and Balloon Angioplasty Comparison (ERBAC) Study. Circulation. 1997; 96(1): 91–
98, doi: 10.1161/01.cir.96.1.91, indexed in Pubmed: 9236422.
3. Onuma Y, Tanimoto S, Ruygrok P, et al. Efficacy of everolimus eluting stent 
implantation in patients with calcified coronary culprit lesions: two-year angiographic
and three-year clinical results from the SPIRIT II study. Catheter Cardiovasc Interv. 
2010; 76(5): 634–642, doi: 10.1002/ccd.22541, indexed in Pubmed: 20690152.
4. Rathore S, Matsuo H, Terashima M, et al. Rotational atherectomy for fibro-calcific 
coronary artery disease in drug eluting stent era: procedural outcomes and 
angiographic follow-up results. Catheter Cardiovasc Interv. 2010; 75(6): 919–927, 
doi: 10.1002/ccd.22437, indexed in Pubmed: 20432398.
5. Abdel-Wahab M, Richardt G, Joachim Büttner H, et al. High-speed rotational 
atherectomy before paclitaxel-eluting stent implantation in complex calcified 
coronary lesions: the randomized ROTAXUS (Rotational Atherectomy Prior to Taxus 
Stent Treatment for Complex Native Coronary Artery Disease) trial. JACC 
Cardiovasc Interv. 2013; 6(1): 10–19, doi: 10.1016/j.jcin.2012.07.017, indexed in 
Pubmed: 23266232.
6. Abdel-Wahab M, Toelg R, Byrne RA, et al. High-Speed rotational atherectomy versus
modified balloons prior to drug-eluting stent implantation in severely calcified 
coronary lesions. Circ Cardiovasc Interv. 2018; 11(10): e007415, doi: 
10.1161/CIRCINTERVENTIONS.118.007415, indexed in Pubmed: 30354632.
7. Ryan TJ, Faxon DP, Gunnar RM, et al. Guidelines for percutaneous transluminal 
coronary angioplasty. A report of the American College of Cardiology/American 
Heart Association Task Force on Assessment of Diagnostic and Therapeutic 
Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary 
Angioplasty). Circulation. 1988; 78(2): 486–502, doi: 10.1161/01.cir.78.2.486, 
indexed in Pubmed: 2969312.
8. Mintz GS, Popma JJ, Pichard AD, et al. Patterns of calcification in coronary artery 
disease. A statistical analysis of intravascular ultrasound and coronary angiography in 
1155 lesions. Circulation. 1995; 91(7): 1959–1965, doi: 10.1161/01.cir.91.7.1959, 
indexed in Pubmed: 7895353.
9. Barbato E, Carrié D, Dardas P, et al. European Association of Percutaneous 
Cardiovascular Interventions. European expert consensus on rotational atherectomy. 
EuroIntervention. 2015; 11(1): 30–36, doi: 10.4244/EIJV11I1A6, indexed in Pubmed:
25982648.
9
10. Safian RD, Feldman T, Muller DW, et al. Coronary angioplasty and Rotablator 
atherectomy trial (CARAT): immediate and late results of a prospective multicenter 
randomized trial. Catheter Cardiovasc Interv. 2001; 53(2): 213–220, doi: 
10.1002/ccd.1151, indexed in Pubmed: 11387607.
11. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial 
infarction. J Am Coll Cardiol. 2012; 60: 1581–98, doi: 10.1016/j.jacc.2012.08.001.
12. Lee MS, Yang T, Lasala J, et al. Impact of coronary artery calcification in 
percutaneous coronary intervention with paclitaxel-eluting stents: Two-year clinical 
outcomes of paclitaxel-eluting stents in patients from the ARRIVE program. Catheter 
Cardiovasc Interv. 2016; 88(6): 891–897, doi: 10.1002/ccd.26395, indexed in 
Pubmed: 26756859.
13. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention 
versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J 
Med. 2009; 360(10): 961–972, doi: 10.1056/NEJMoa0804626, indexed in Pubmed: 
19228612.
14. Oei HHS, Vliegenthart R, Hofman A, et al. Risk factors for coronary calcification in 
older subjects. The Rotterdam Coronary Calcification Study. Eur Heart J. 2004; 25(1):
48–55, doi: 10.1016/j.ehj.2003.10.008, indexed in Pubmed: 14683742.
15. Khalid N, Javed H, Shlofmitz E, et al. Adverse events and modes of failure related to 
rotational atherectomy system: the utility of the MAUDE database. Cardiovasc 
Revasc Med. 2021; 27: 57–62, doi: 10.1016/j.carrev.2020.08.038, indexed in Pubmed:
33071196.
16. Cannon C, Braunwald E, McCabe C, et al. Intensive versus Moderate Lipid Lowering
with Statins after Acute Coronary Syndromes. N Engl J Med. 2004; 350(15): 1495–
1504, doi: 10.1056/nejmoa040583.
17. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac
ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the 
thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999; 100(15): 
1593–1601, doi: 10.1161/01.cir.100.15.1593, indexed in Pubmed: 10517729.
Table 1. Baseline characteristics in patients undergoing rotational atherectomy.
Patient characteristics
Overall Rotapro Rota
P(n = 597) (n = 246) (n = 351)
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Age [years]a 72.9 ± 9.1 73.0 ± 9.0 72.8 ± 9.2 0.71
Men 79.7% 78.9% 80.3% 0.65
BMI [kg/m2]a 27.7 ± 4.4 27.7 ± 4.1 27.8 ± 4.5 0.78
eGFR [mL/min/1.73 m2] 66.3 ± 21.0 65.7 ± 20.25 64.65 ± 22.5 0.55
Heart failure (37) 6.3% (12) 5.1% (25) 7.1% 0.34
NYHA classification:
0.34
I (89) 14.9% (45) 18.3% (44) 12.6% 
II (272) 45.5% (111) 45.2% (160) 45,7% 
III (212) 35.5% (80) 32.5% (132) 37.5% 
IV (24) 4.1% (10) 4.1% (14) 4.1% 
CAD presentation: 0.02*
   ACS (100) 16.8% (31) 12.6% (69) 19.7% 
   No ACS (497) 83.2% (215) 87.4% (282) 80.3% 
CTO vessel (216) 36.2% (90) 36.7% (126) 35.9% 0.83
Diabetes mellitus (224) 37.6% (86) 35.1% (138) 39.3% 0.32
Dyslipidemia (537) 90.0% (233) 94.3% (304) 87,1% 0.006*
Hypertension (552) 92.5% (222) 90.3% (330) 93,8% 0.11
Current smoker (63) 10.5% (24) 9.8% (39) 11,0% 0.65
LVEF [%]: 0.37
> 51 (381) 63.9% (163) 66.4% (218) 62.2% 
41–51 (116) 19.4% (40) 16.2% (76) 21.8% 
30–40 (63) 10.6% (29) 11.8% (34) 9.8% 
0–29 (36) 6.1% (14) 5.7% (16) 6.3% 
Family history of CAD (206) 34.6% (84) 34.0% (122) 35.0% 0.82
Prior MI (206) 34.5% (78) 31.9% (128) 36.3% 0.30
Prior CABG (180) 30.1% (59) 23.9% (121) 34.4% 0.009*
Prior stroke (8) 1.3% (17) 0.4% (7) 2.0% 0.10
LDL max. [mg/dL] 95.8 ± 35.8 95.2 ± 37.4 96.2 ± 34.7 0.74
Positive stress test (478) 80.0% (218) 88.4% (260) 73.6% 0.02
Values are given as percentages of patients and numbers or as mean and standard deviation. ACS — acute coronary
syndrome; BMI — body mass index; CABG — coronary artery bypass grafting; CAD — coronary artery disease; 
CTO — chronic total occlusion; eGFR — estimated glomerular filtration rate; LDL — low-density lipoprotein; 
LVEF — left ventricular ejection fraction; MI — myocardial infarction; NYHA — New York heart Association; 
PCI — percutaneous coronary intervention
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Table 2. Characteristics retrieved from coronary angiography
Table 3. Characteristics related to percutaneous coronary intervention (PCI) and rotational 
atherectomy system.
Overall procedural results 
Overall Rotapro Rota
P 
(n = 597) (n = 246) (n = 351)
Balloon diameter predilatation [mm] 2.9 ± 0.6 3.1 ± 0.5 2.8 ± 0.6 0.0001*
Balloon diameter postdilatation [mm] 3.8 ± 0.7 3.9 ± 0.6 3.8 ± 0.7 0.07
Inflation pressure predilatation [atm] 21.7 ± 11.9 21.6 ± 16.3 21.8 ± 7.9 0.88





(n=597)  (n=246) (n=351)
Target vessel: 0.095
Left main (86) 14.4% (35) 14.2% (51) 14.5% 
Right coronary artery (250) 41.9% (95) 38.6% (155) 44.2% 
Left circumflex artery (100) 16.7% (37) 15.0% (63) 17.9% 
Left anterior descending artery (159) 26.6% (79) 32.1% (80) 22.8% 
Single vein graft (2) 0.3% (0) 0.0% (2) 0.6% 
Lesion length [mm] 0.151
< 10 mm (21) 3.6% (9) 3.8% (12) 3.5% 0.922
10–20 mm (161) 27.1% (68) 28.3% (93) 27.0% 
> 20 mm (405) 68.0% (163) 67.9% (240) 69.5% 
AHA/ACC classification 0.531
A/B1 (12) 2.1% (6) 2.5% (6) 1.7% 
B2 (108) 18.1% (48) 19.6% (60) 17.1% 
C (476) 79.8% (191) 78.0% (285) 81.2% 
Calcification 0.886
None (4) 0.7% (2) 0.4% (2) 0.6% 
Mild (14) 2.3% (7) 2.9% (7) 2.0% 
Moderate (70) 11.7% (30) 12.2% (40) 11.4% 
Severe (508) 85.2% (207) 84.5% (301) 86.0% 
Excentric calcification (357) 59.7% (123) 50.4% (234) 66.7% 0.0001*
Tortuosity (143) 24.1% (52) 21.3% (91) 26.1% 0.182
Relevant side branch (153) 25.7% (53) 21.7% (100) 28.6% 0.061
Intra-lesion angulation: 0.049
None (77) 12.9% (41) 16.8% (36) 10.3% 
< 45% (205) 34.5% (72) 29.5% (133) 38.0% 
45–90% (264) 44.3% (110) 45.1% (154) 43.7% 
> 90% (49) 8.2% (21) 8.6% (28) 8.0% 
Values are given as percentages of patients and numbers. AHA/ACC — American Heart Association/American College
of Cardiology 
Diameter stenosis pre PCI [%] 88 ± 14 87 ± 15 88 ± 14 0.70
Diameter stenosis post PCI [%] 2 ± 13 1 ± 10 3 ± 14 0.07
Number of stents implanted 1.9 ± 1.1 1.9 ± 1.1 1.8 ± 1.1 0.78
Stent diameter [mm] 3.4 ± 0.6 3.5 ± 0.5 3.5 ± 0.6 0.27
Overall stent length [mm] 52.7 ± 31.6 50.5 ± 30.3 54.2 ± 32.5 0.23
Burr size (n) % 0.0001*
1.25 mm (130) 21.8% (26) 10.5% (104) 30.1% 
1.50 mm (262) 44.0% (117) 47.4% (145) 42.2% 
1.75 mm (172) 28.9% (87) 35.4% (85) 24.7% 
2.00 mm (27) 4.5% (16) 6.7% (17) 3.0%  
Access site (n) % 0.0024*
Single radial access (201) 33.7% (100) 40.7% 28.7% (102)
Any femoral access (396) 66.3% (146) 59.3% (249) 71.3% 
Guiding catheter size (n) % 0.0007*
6 Fr (194) 31.5% (58) 23.6% (136) 38.8% 
7 Fr (349) 58.5% (161) 65.5% (186) 52.9% 
8 Fr (56) 9.4% (27) 11.0% (29) 8.3% 
Values are given as percentages of patients and numbers or as median and interquartile range. 
Table 4. Study endpoints and major complications.
Total number




(n = 351) P 
Primary endpoint (n) %
In-hospital MACCE: (29) 4.9% (9) 3.7% (20) 5.7% 0.254
Mortality (15) 2.5% (6) 2.4% (9) 2.6% 0.923
MI type 4a (4) 0.7% (17) 0.4% (3) 0.9% 0.647
TVR (20) 3.4% (7) 2.9% (13) 3.7% 0.566
Stroke (17) 0.2% (0) 0.0% (17) 0.3% 1.000
Secondary procedural endpoints (n) %
Technical success (589) 98.7% (244) 99.2% (345) 98.3% 0.385
Procedural success (568) 93.8% (237) 95.5% (331) 92.6% 0.318
Procedural time [min] 88 [62–132] 82.5 [57–119] 96 [67–146.5] 0.0003*
Fluoroscopy time [min] 34 [23–56] 30 [21–50] 38 [25–63.5] 0.0001*
Contrast volume used [mL] 250 [180–350] 210 [160–300] 290 [150–380] 0.0001*
Dose area product 
[cGy*cm2] 8011 [4758–14062] 6129.5 [3563–9939] 9827 [6098–16402] 0.0001*
Major complications (n) %
Pericadiocentesis (8) 1.3% (2) 0.8% (6) 1.7% 0.348
Vascular access 
complication (13) 2.1% (8) 3.45% (5) 1.46% 0.206
Values are given as percentages of patients and numbers or as median and interquartile range; bold — 
statistically significant with p < 0.05; MACCE — major adverse cardiac and cerebrovascular events; MI —
13
myocardial infarction; TVR — target vessel revascularization 
Table 5. Multivariable logistic regression analysis to predict the primary endpoint of in-
hospital major adverse cardiac and cerebrovascular events.
Figure 1. Components of the primary endpoint of in-hospital major adverse cardiovascular 
and cerebral events (MACCE) including pericardiocentesis during in the conventional 





OR 95% CI P OR CI 95% P 
ACS 3.29 1.46–7.11 0.005* 1.86 0.65–4.65 0.23
History of CABG 0.47 0.14–1.29 0.15 0.48 0.14–1.31 0.16
Positive stress test 2.34 0.42–44.0 0.38 – -
Excentric calcification 0.89 0.42–1.97 0.42 -
Intra-lesion angulation 
> 45%
1.18 0.54–2.77 0.68 1.17 0.49–3.11 0.73
ACS — acute coronary syndrome; CABG — coronary artery bypass grafting; CAD — coronary artery disease; CI — 
confidence interval; LVEF — left ventricular ejection fraction; OR — odds ratio

